Physician profile
Jodie L Delesio
NPI 1407289192
$49,597.92
in general payments reported to CMS, 2019-2025
39 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $11K · 2023: $7,473 · 2024: $1,563 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,820 · Consulting Fee: $2,748 · Honoraria: $2,420 · Travel and Lodging: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,564.66 |
| Food and Beverage | $2,820.30 |
| Consulting Fee | $2,748.00 |
| Honoraria | $2,420.00 |
| Travel and Lodging | $1,191.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $12,726.90 | 2021-2025 | Xpovio |
| Janssen Biotech, INC. | $12,022.20 | 2022-2025 | Carvykti, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $8,826.47 | 2021-2025 | Reblozyl |
| Secura Bio, INC. | $6,850.14 | 2021-2025 | Copiktra |
| Celgene Corporation | $6,494.92 | 2021-2024 | Reblozyl |
| Genzyme Corporation | $435.84 | 2021-2025 | |
| Beigene USA, INC. | $194.58 | 2022-2025 | Brukinsa |
| Amgen INC. | $173.24 | 2021-2022 | |
| Glaxosmithkline, LLC. | $167.77 | 2022-2024 | Ojjaara |
| Astrazeneca Pharmaceuticals Lp | $145.59 | 2021-2024 | Imfinzi |
| Genmab U.S., INC. | $141.59 | 2023 | Epkinly, Tivdak |
| Genentech USA, INC. | $141.56 | 2021-2025 | Tecentriq, Polivy, Lunsumio |
| Gilead Sciences, INC. | $124.59 | 2023 | |
| Novartis Pharmaceuticals Corporation | $123.78 | 2021-2024 | |
| Seagen INC. | $119.29 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodie Delesio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.